TCF3 and hemoglobin measurement: This work establishes how 3D epigenomic reprogramming cooperates with redox adaptation to drive HB pathogenesis, positioning the TCF3-TRIB2-NRF2 axis as a promising biomarker and therapeutic target in HB.